Exceptional purity for peptide research
We've been sourcing research-grade peptides for several years. Rainbow Peptide's vials consistently pass our HPLC verification, purity exceeds 98% every batch. COA matched our internal testing exactly.
Cardarine (GW501516) powder 1g, ≥98% HPLC purity, COA verified. PPARδ agonist used in fatty acid oxidation, metabolic syndrome, and exercise mimetic research. For research use only.
In Stock, Overnight and 2–3 day delivery available
Cardarine (GW501516, GW1516) is a PPARδ (peroxisome proliferator-activated receptor delta) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals. Although not a SARM by mechanism (PPARδ is a nuclear receptor in the fatty acid oxidation pathway, not the androgen receptor), it is frequently categorised alongside SARMs in research compound literature due to similar distribution channels and research applications.
GW501516 activates PPARδ, a nuclear receptor that regulates genes involved in fatty acid catabolism, mitochondrial biogenesis, and glucose utilisation. PPARδ activation in skeletal muscle promotes the type I (slow-twitch, oxidative) fibre phenotype, increases fatty acid oxidation, reduces intramyocellular lipid accumulation, and upregulates GLUT4 expression. In adipose tissue, it promotes fat mobilisation and reduces lipogenesis.
GW501516 is widely used in: metabolic syndrome models (insulin resistance, dyslipidaemia), exercise biology and "exercise mimetic" research, cardiovascular disease models (HDL elevation, endothelial function), and skeletal muscle fibre-type transition studies. The "exercise-in-a-pill" characterisation in rodent studies (Narkar et al., Cell 2008) established GW501516 as a key tool compound in metabolic biology.
Powder is the preferred format for in vitro cell culture (adipocytes, myocytes, hepatocytes) and rodent metabolic studies. Soluble in DMSO (≥50mg/mL). Standard in vivo dosing: 5–10mg/kg/day oral gavage in rodent studies.
GW501516's clinical development was discontinued by GSK following carcinogenicity signals observed in long-term rodent studies (5–30 mg/kg over 104 weeks). This history is well documented in the pharmacology literature and is a standard reference point in PPARδ agonist research; as with any long-term small-molecule dosing study, in vivo protocols should be designed with appropriate institutional oversight.
Purity: ≥98% (HPLC verified) | Format: Lyophilised powder | Quantity: 1g
Rainbow Peptide works with independent, accredited third-party laboratories, including Vanguard Laboratory (ISO 17025:2017-accredited, A2LA Certificate #6377.01.01), to verify compound identity and purity. A Certificate of Analysis is included with every order.
For research use only. Not for human consumption.
Third-Party Verified
We don't just claim purity, we prove it. Every batch of Cardarine GW501516 Powder 1g is independently tested by an accredited third-party laboratory before it reaches you. Your COA is linked to your specific lot number.
Verified purchases from active research labs and scientists
We've been sourcing research-grade peptides for several years. Rainbow Peptide's vials consistently pass our HPLC verification, purity exceeds 98% every batch. COA matched our internal testing exactly.
Third order now. Consistent batch-to-batch results matter enormously in long-term research. Certificate of Analysis is detailed with mass spec data. Would not switch sources.
Verified against our reference standards. Purity >98.2% by HPLC. Packaging was appropriate for temperature-sensitive peptides. Will re-order.